17681-30-0

Usage

Uses

Used in Pharmaceutical Industry:
BENZOTHIAZOL-2-YLMETHYL-METHYL-AMINE is used as a chemical intermediate for the synthesis of various pharmaceutical products. Its role in the industry is crucial for the development of new drugs and medications, contributing to the advancement of healthcare and treatment options. Due to its chemical properties, it serves as a building block in the creation of complex molecules with potential therapeutic applications.

InChI:InChI=1/C9H10N2S/c1-10-6-9-11-7-4-2-3-5-8(7)12-9/h2-5,10H,6H2,1H3/p+1

Upstream product

• 95-16-9 1,3-Benzothiazole 
• 127-19-5 N,N-dimethyl acetamide 
• 106086-78-6 2-(bromomethyl)-1,3-benzothiazole 
• 74-89-5 methylamine 
• 2516-40-7 2-bromo-1,3-benzothiazole 
• 2083-91-2 N,N-Dimethyltrimethylsilylamine 
• 120-75-2 2-Methylbenzothiazole 
• 6639-57-2 benzothiazole-2-carbaldehyde 

Downstream Products

• 17681-32-2 N-(2-benzothiazolylmethyl)-N-methylbenzamide 
• 1203604-81-2 N-(1,3-benzothiazol-2-ylmethyl)-5-(2,6-dimethoxyphenyl)-N-methyl-1,2,4-triazin-3-amine 

Relevant academic research and scientific papers

tert-Butoxy-Radical-Promoted α-Arylation of Alkylamines with Aryl Halides

In the presence of a tert-butoxy radical precursor, the reaction of alkylamines with aryl halides was found to give α-arylated alkylamines through homolytic aromatic substitution of the halogen atoms.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial Fab I and can be used for the treatment of Staphylococcal infections.

New 1,2,4-triazine derivatives and biological applications thereof

The invention relates to new 1,2,4-triazine derivatives of formula (I): wherein A, B, R2 and Y are defined in the application, their preparation and intermediates, their use as drugs and pharmaceutical compositions and associations containing them. The compounds of formula (I) are capable of inhibiting bacterial heptose synthesis.

Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity

Vitronectin receptor antagonists having the formula: STR1 which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.